Randomized controlled trial of tolvaptan and carperitide to fluid retention in patients with congestive heart failure

INTERVENTION: Tolvaptan group: 7.5‐15mg/day oral administration Carperitide group: 0.0125‐0.025µg/kg/min continuous intravenous administration (‐0.2µg/kg depending on the condition) CONDITION: Acute congestive heart failure (including acute exacerbation of chronic heart failure) patietnts PRIMARY OUTCOME: Daily urine volume of first, second, third, fourth, seventh, and day 14th after admission (or dicharge) SECONDARY OUTCOME: Body weight of subjective symptoms INCLUSION CRITERIA: (1) Patients with fluid retention in congestive heart failure (2) Patients who were hospitalized for treatment of heart failure